PUBLISHER: The Business Research Company | PRODUCT CODE: 2127589
PUBLISHER: The Business Research Company | PRODUCT CODE: 2127589
A ribonucleic acid (RNA) in situ hybridization (ISH) is a molecular method used to detect and visualize specific RNA sequences within cells or tissue samples. It allows researchers and clinicians to determine the localization and expression patterns of target RNA molecules while maintaining the structural integrity of the sample. A ribonucleic acid (RNA) in situ hybridization (ISH) uses labeled complementary probes that attach to specific RNA targets for microscopic detection and analysis.
The primary product types of ribonucleic acid (RNA) in situ hybridization (ISH) include probes, kits and reagents, instruments, and services. Probes refer to labeled nucleic acid sequences developed to identify and bind with specific RNA targets within cells or tissue samples. These products utilize technologies such as fluorescence in situ hybridization, chromogenic in situ hybridization, and ribonucleic acid scope. The major applications include diagnostic applications, cancer research, infectious diseases, neuroscience, developmental biology, and gene expression studies, while the end-users comprise academic and research institutes, pharmaceutical and biotechnology companies, and clinical laboratories.
Tariffs are influencing the ribonucleic acid (RNA) in situ hybridization (ISH) market by increasing the cost of imported probes, imaging systems, and specialized reagents used in molecular diagnostics and research workflows. This is extending procurement timelines and increasing operational expenses across product segments such as probes, kits and reagents, instruments, and automated hybridization systems, particularly in regions such as Asia-Pacific and Europe that depend heavily on imported laboratory technologies. Diagnostic laboratories and academic research institutes are also experiencing delayed access to advanced imaging and sequencing-compatible tools due to ongoing global supply chain disruptions. However, tariffs are encouraging localized manufacturing, regional supplier diversification, and greater investment in domestic biotechnology ecosystems, which may enhance long-term supply resilience and innovation capacity.
The ribonucleic acid (rna) in situ hybridization (ish) market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (rna) in situ hybridization (ish) market statistics, including ribonucleic acid (rna) in situ hybridization (ish) industry global market size, regional shares, competitors with a ribonucleic acid (rna) in situ hybridization (ish) market share, detailed ribonucleic acid (rna) in situ hybridization (ish) market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) in situ hybridization (ish) industry. This ribonucleic acid (rna) in situ hybridization (ish) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ribonucleic acid (RNA) in situ hybridization (ish) market size has grown rapidly in recent years. It will grow from $1.49 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to growth in cancer biomarker research, expansion of academic molecular biology funding, increasing adoption of fluorescence microscopy techniques, rising prevalence of infectious disease diagnostics, development of early nucleic acid detection methods.
The ribonucleic acid (RNA) in situ hybridization (ish) market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising demand for precision oncology diagnostics, increasing adoption of spatial transcriptomics technologies, expansion of personalized medicine applications, growth in automated laboratory workflows, increasing investment in advanced genomic research infrastructure. Major trends in the forecast period include AI assisted spatial transcriptomics image analysis improving rna signal interpretation accuracy, ultra sensitive multiplex probe development enabling simultaneous multi target rna detection, automated slide hybridization platforms reducing manual error and improving throughput, advanced fluorescent imaging systems enabling high resolution intracellular rna mapping, single cell expression profiling innovations enhancing tissue level gene expression insights.
The rising infectious disease detection is expected to propel the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market going forward. Infectious disease detection refers to the growing application of diagnostic methods to identify viral, bacterial, and other pathogenic infections through molecular and laboratory-based analyses. The increase in infectious disease detection is driven by the expanding adoption of advanced molecular diagnostic technologies that provide faster and more accurate pathogen identification. RNA in situ hybridization (ISH) enhances infectious disease detection by identifying and localizing pathogen-specific RNA within tissue specimens, enabling precise visualization of infected cells while preserving tissue morphology. For instance, in May 2026, according to the UK Health Security Agency, a UK-based government agency, between 1 January and 25 May 2026, England reported 630 laboratory-confirmed measles cases, marking an increase of 88 cases compared with the previous report published on 11 May 2026. Therefore, the rising infectious disease detection is driving the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market.
The increasing adoption of precision medicine is expected to propel the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market going forward. Precision medicine is a healthcare approach that tailors disease prevention, diagnosis, and treatment based on an individual's genetic profile, biomarkers, and molecular characteristics. The adoption of precision medicine is rising due to the increasing prevalence of chronic diseases, particularly cancer, which require highly targeted and personalized treatment strategies. RNA in situ hybridization (ISH) supports precision medicine by detecting and localizing specific RNA biomarkers within tissue samples, facilitating molecular profiling that guides targeted therapies and enhances patient-specific treatment outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from six in 2022. Therefore, the increasing adoption of precision medicine is driving the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market.
Major companies operating in the ribonucleic acid (RNA) in situ hybridization (ISH) market are prioritizing strategic partnerships to advance workflow automation, enhance RNA biomarker visualization, improve diagnostic accuracy, and support high-throughput molecular pathology analysis. Strategic partnerships are collaborative agreements between organizations that combine resources, expertise, or capabilities to achieve common objectives, expand market reach, and foster mutual growth. For instance, in March 2026, Leica Biosystems Nussloch GmbH, a Germany-based medical technology manufacturer, partnered with Bio-Techne Corporation, a US-based life sciences company, to introduce BOND-PRIME RNAscope Brown Detection, designed to enhance automated chromogenic RNA in situ hybridization workflows, improve RNA biomarker visualization, and support high-throughput digital pathology and molecular diagnostics applications. Its key distinguishing feature is the fully automated integration of the RNAscope in situ hybridization (ISH) workflow with the BOND-PRIME Staining Platform, enabling faster, standardized RNA biomarker detection while minimizing manual intervention.
Major companies operating in the ribonucleic acid (RNA) in situ hybridization (ish) market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Charles River Laboratories, QIAGEN N.V., Bio-Techne Corporation, Akoya Biosciences Inc., Biocare Medical LLC, Biogenex Laboratories Inc., Empire Genomics LLC, BioChain Institute Inc., Boster Biological Technology Co. Ltd., AnaPath Services GmbH, Bio SB Inc., Enzo Biochem Inc.
North America was the dominating region in the ribonucleic acid (RNA) in situ hybridization (ISH) market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) in situ hybridization (ISH) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the ribonucleic acid (RNA) in situ hybridization (ISH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The ribonucleic acid (RNA) in situ hybridization (ISH) market consists of revenues earned by entities by providing services such as biomarker identification, molecular pathology testing, and tissue-based diagnostic research. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA) in situ hybridization (ISH) market also includes sales of assay controls, detection substrates, hybridization buffers, target-specific RNA probes. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses ribonucleic acid (rna) in situ hybridization (ish) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for ribonucleic acid (rna) in situ hybridization (ish) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna) in situ hybridization (ish) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.